22157.jpg
Exosome Therapeutics Pipeline research 2024
June 19, 2024 07:45 ET | Research and Markets
Dublin, June 19, 2024 (GLOBE NEWSWIRE) -- The "Exosomes - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering.An array of drugs is currently moving through various...
22157.jpg
Genomics Collaboration, R&D, and Licensing Deals Analysis Report 2024 with Directory of 948 Agreements Signed Since 2016
May 07, 2024 07:14 ET | Research and Markets
Dublin, May 07, 2024 (GLOBE NEWSWIRE) -- The "Genomic Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering.Genomic Collaboration and Licensing...
3logos.jpg
Transgene et NEC présentent les premiers signes de bénéfice clinique de leur vaccin individualisé contre le cancer, TG4050, dans les cancers de la tête et du cou à l’AACR 2024
April 09, 2024 11:45 ET | Transgene S.A.
Les nouvelles données immunologiques de Phase I confirment la forte immunogénicité de TG4050 dans le traitement adjuvant des cancers de la tête et du cou.Tous les patients traités sont encore en...
3logos.jpg
Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024
April 09, 2024 11:45 ET | Transgene S.A.
Extensive Phase I immunology data confirm strong immunogenicity of TG4050 in the adjuvant treatment of head and neck cancers. All treated patients remain disease-free after a median follow-up of...
22157.jpg
Viral Vector and Plasmid DNA Technologies Market Outlook 2024-2028: Innovations, Technological Advances and Product Launches from Leading Companies
April 05, 2024 04:02 ET | Research and Markets
Dublin, April 05, 2024 (GLOBE NEWSWIRE) -- The "Viral Vector and Plasmid DNA: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering. The global market for...
3logos1.png
Transgene et NEC étendent leur collaboration et poursuivent ensemble le développement clinique de TG4050, un vaccin thérapeutique individualisé contre le cancer
January 08, 2024 11:45 ET | Transgene S.A.
Transgene et NEC prévoient de lancer, en 2024, une extension de l’étude randomisée de Phase I en essai randomisé de phase I/II pour continuer à démontrer le potentiel de TG4050 comme traitement...
3logos1.png
Transgene and NEC Extend their Collaboration to Continue Joint Clinical Development of Neoantigen Cancer Vaccine TG4050
January 08, 2024 11:45 ET | Transgene S.A.
Transgene and NEC plan to start an extension of the randomized Phase I trial into a randomized Phase I/II study in 2024 to further demonstrate the potential of TG4050 as an adjuvant treatment of...
GMILogo_Vertical-Gradient.png
Gene Therapy Market to hit USD 44.5 billion by 2032, says Global Market Insights Inc.
August 07, 2023 17:30 ET | Global Market Insights Inc.
Selbyville, Delaware, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Gene Therapy Market size is expected to be worth USD 44.5 billion by 2032. The growing adoption of personalized medicine is generating...
22157.jpg
Unlocking New Frontiers in Malignancy Treatment: Cell Therapy Clinical Activity and Process Automation Research Report 2023
August 03, 2023 07:43 ET | Research and Markets
Dublin, Aug. 03, 2023 (GLOBE NEWSWIRE) -- The "Cell Therapy Clinical Activity and Process Automation" report has been added to ResearchAndMarkets.com's offering. Cell therapy, a revolutionary...
22157.jpg
Global Cloning & Mutagenesis Market Report 2023: Increasing Research and Development Activities in Cancer and Other Chronic Disorders Fuels Growth
April 18, 2023 11:58 ET | Research and Markets
Dublin, April 18, 2023 (GLOBE NEWSWIRE) -- The "Cloning & Mutagenesis Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F Segmented By Gene Type (Standard v/s...